Searching For Real Value In Market Debris At Verve Therapeutics Inc (NASDAQ: VERV)

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Yahoo Finance discussed the stock recently as it posted Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

As a NASDAQ listed company, VERV falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $13.09 and fluctuated between $13.32 as its day high and $12.64 as its day low. The current market capitalization of Verve Therapeutics Inc is $1.03B. A total of 0.69 million shares were traded on the day, compared to an average of 1.24M shares.

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, VERV has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.

In the most recent transaction, Dorval Allison sold 554 shares of VERV for 11.45 per share on Nov 29. After the transaction, the Chief Financial Officer now owns 4,060 company shares.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for VERV in the last 3 months, the mean price target is $45.89 with high estimates of $75.00 and low estimates of $22.00. In terms of 52-week highs and lows, VERV has a high of $21.49 and a low of $8.22.

As of this writing, VERV has an earnings estimate of -$0.82 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$0.93. The company reported an EPS of -$0.87 in the last quarter, which was 5.40% higher than expectations of -$0.92.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. VERV’s latest balance sheet shows that the firm has $360.44M in Cash & Short Term Investments as of fiscal 2021. There were $1.96M in debt and $22.02M in liabilities at the time. Its Book Value Per Share was $7.22, while its Total Shareholder’s Equity was $357.35M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VERV is Buy with a score of 4.18.

Most Popular

Related Posts